Influence of kinins and angiotensin II on the regulation of papillary blood flow.
The influence of kinins and angiotensin II on the regulation of renal cortical and papillary blood flow and sodium and water excretion was examined in rats. Superficial cortical and papillary blood flows were measured using a laser-Doppler flowmeter. Papillary blood flow increased 50% after enalaprilat (60 micrograms/kg) and phosphoramidon (5.5 micrograms.kg-1.min-1) were given along with 0.3 M sodium bicarbonate solution to inhibit degradation of kinins and enhance urinary kallikrein activity. Infusion of a kinin antagonist, D-Arg-Hyp-Thi-D-Phe-bradykinin (5 micrograms/min), returned papillary blood flow to control levels. Urine flow and sodium excretion increased after the administration of the kininase inhibitors and sodium bicarbonate, while glomerular filtration rate (GFR) and outer cortical blood flow were unaltered. The kinin antagonist did not alter sodium and water excretion in rats receiving the kininase inhibitors and bicarbonate. Administration of the kinin antagonist alone lowered papillary blood flow by 20%, without affecting outer cortical blood flow or GFR. Urine flow decreased and urine osmolality increased after the rats received the kinin antagonist, but sodium excretion remained unaltered. To assess the role of angiotensin II in the control of papillary blood flow, kinin receptors were blocked by infusion of an antagonist, and the effects of enalaprilat and saralasin were studied. Papillary blood flow increased after blockade of the angiotensin II system in rats receiving the kinin antagonist. These results indicate that the kallikrein-kinin and renin-angiotensin systems participate in the regulation of papillary blood flow.
Roman
R J
RJ
Department of Physiology, Medical College of Wisconsin, Milwaukee, Wisconsin 53226.
Kaldunski
M L
ML
Scicli
A G
AG
Carretero
O A
OA
D000804:Angiotensin II / Q000502:physiology*; D000818:Animals; D001639:Bicarbonates / Q000494:pharmacology; D001920:Bradykinin / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors / Q000494:pharmacology; D004656:Enalapril / Q000494:pharmacology; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006020:Glycopeptides / Q000494:pharmacology; D007672:Kidney Cortex / Q000098:blood supply; D007679:Kidney Medulla / Q000098:blood supply*; D007705:Kinins / Q000502:physiology*; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D012016:Reference Values; D012039:Regional Blood Flow / Q000187:drug effects; D012504:Saralasin / Q000494:pharmacology; D012964:Sodium / Q000494:pharmacology; D017693:Sodium Bicarbonate
D001639:Bicarbonates; D006020:Glycopeptides; D007705:Kinins; C053748:B 4162; D000804:Angiotensin II; D004656:Enalapril; D017693:Sodium Bicarbonate; D012964:Sodium; D012504:Saralasin; D001920:Bradykinin; C008890:phosphoramidon